We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 249

DEA Schedules a FDA-Approved CBD Drug
  • McDermott Will & Emery
  • USA
  • October 5 2018

As beverage manufacturers mull the creation and distribution of cannabidiol (CBD)-infused products, the US Drug Enforcement Administration’s (DEA)


Printed Publication Status Based on Public Accessibility
  • McDermott Will & Emery
  • USA
  • August 30 2018

Addressing public accessibility of prior art, the US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB)


Obviousness Cannot Be Predicated on What Is Unknown
  • McDermott Will & Emery
  • USA
  • August 30 2018

The US Court of Appeals for the Federal Circuit upheld a district court finding that the patent challenger failed to prove that patents directed to a


The Latest: FTC to Look Closely at Competition between Biologics and Biosimilars and Patent Protection Strategies of Branded Manufacturers
  • McDermott Will & Emery
  • USA
  • July 24 2018

On July 18, 2018, US Food and Drug Administration (FDA) Commissioner Scott Gottlieb delivered a speech at The Brookings Institution in Washington, DC


Teva’s Skinny Label Found Not to Induce Infringement by Off-Label Use
  • McDermott Will & Emery
  • USA
  • July 18 2018

The US District Court for the District of Delaware granted in part Teva Pharmaceuticals' renewed motion for judgment as a matter of law (JMOL)


How Many Infringers Does It Take to “Administer” a Medication?
  • McDermott Will & Emery
  • USA
  • July 18 2018

Addressing the issue of whether defendant's abbreviated new drug application (ANDA) formulation would infringe plaintiff's method patents under a


Second Circuit’s Mandate Rule Limits New Causation Theories on Remand
  • McDermott Will & Emery
  • USA
  • July 18 2018

On remand, indirect purchasers of the drug ACTOS sought to amend their antitrust complaint to modify their causal theory of harm. The district court


Stability of Ready-to-Use Dexmedetomidine Not Inherent
  • McDermott Will & Emery
  • USA
  • July 18 2018

After a bench trial, the US District Court for the District of Delaware found several Hospira patents covering a diluted, "ready-to-use" composition


Lower Court’s Factual Finding Given Deference in “Close Case”
  • McDermott Will & Emery
  • USA
  • June 28 2018

The US Court of Appeals for the Federal Circuit affirmed the district court's finding that a skilled artisan would have had no reasonable expectation


Recycle, Recycle, Recycle: Key Considerations for Research, Medical Education, and Other Secondary Uses of Data
  • McDermott Will & Emery
  • USA
  • June 6 2018

The digitization of health care and the proliferation of electronic medical records is happening rapidly, generating large quantities of data with